Triptorelin (Trelstar)

Indicated for tretment of advanced prostate cancer.

An alternative to orchiectomy for management of prostate cancer.

Available as every four or twelve week injections.

A potent repressor of gonadotropin secretion when given continuously and in therapeutic doses.

Following initial administration, there may be a surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol.

Following chronic and continuous administration, usually two to four weeks, a sustained decrease in LH and FSH secretion and marked reduction of testicular and ovarian steroidogenesis occurs.

Serum testosterone concentration can fall to surgically castrated levels.

Adverse events include:Fatigue, nausea, vomiting, decreased blood cell counts, hair loss, mouth sores! hot flashes, loss of libido and breast tenderness.

Phase 3PROMISE-GIM6 study showed temporary ovarian suppression during chemotherapy induced by LHRHa Triptorelin significantly reduces the occurrence of treatment related early menopause (no resumption of menstrual activity and postmenopausal levels of FSH and estradiol for one year after the last cycle of chemotherapy) from 25.9 percent to 8.9% without increasing incidence of LHRHa related toxicities search his cock flashes, headache, sweating, mood modification, and vaginal dryness.

Leave a Reply

Your email address will not be published. Required fields are marked *